• Explore /
  • Poster
  • / A multicenter, randomized phase II study of total neoadjuvant therapy (TNT) with FOLFIRINOX (FFX) and SBRT, with or without losartan (L) and nivolumab (N) in borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC).

A multicenter, randomized phase II study of total neoadjuvant therapy (TNT) with FOLFIRINOX (FFX) and SBRT, with or without losartan (L) and nivolumab (N) in borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC).

Abstract Poster

Authors

null

Theodore S. Hong

NRG Oncology and Massachusetts General Hospital, Harvard Medical School, Boston, MA;

Theodore S. Hong , Beow Y. Yeap , Nora K. Horick , Jennifer Yon-Li Wo , Colin D. Weekes , Jill N. Allen , Motaz Qadan , Paul Eliezer Oberstein , Rakesh K. Jain , Lawrence Scott Blaszkowsky , Brian M. Wolpin , Daniel A. Laheru , Wells A. Messersmith , Leilana Ly , Lorraine C. Drapek , David Tsai Ting , Richard A. Burkhart , Carlos Fernandez-del Castillo , Alec Kimmelman , David P. Ryan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03563248

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 719)

DOI

10.1200/JCO.2023.41.4_suppl.719

Abstract #

719

Poster Bd #

L6

Abstract Disclosures

Similar Posters

First Author: Eric Christenson

First Author: Fergus Keane

First Author: Kelsey Klute

First Author: Dong Ho Lee